Biotech · Private company
Ikena Oncology
Track this companyFree. Adds Ikena Oncology to your Dealase workspace and tells you when its record changes.
Clinical trials60 recruiting or active
Pipeline programs14From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline14
- Combination Therapy: PY314 + PembrolizumabPhase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- IK-175Phase 1 · Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- IK-175 + nivolumabPhase 1 · Head and Neck Squamous Cell CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- IK-175 and nivolumabPhase 1 · Urothelial CarcinomaClinicalTrials.gov · fetched Nov 12, 2026
- IK-595Phase 1 · Solid Tumor, AdultClinicalTrials.gov · fetched Nov 12, 2026
- IK-930Phase 1 · Solid Tumors, AdultClinicalTrials.gov · fetched Nov 12, 2026
- OsimertinibPhase 1 · Solid Tumors, AdultClinicalTrials.gov · fetched Nov 12, 2026
- PY159 Single agent dose level 1Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- PY159 Single agent dose level 2Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- PY159 Single agent dose level 3Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- PY159 Single agent dose level 4Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- PY159 Single agent dose level 5Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- PY159 Single agent dose level 6Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
- PY314Phase 1 · Advanced Solid TumorClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials6
- Study of IK-595 in RAS- or RAF-altered Advanced TumorsPHASE1 · TERMINATED · started Dec 18, 2023ClinicalTrials.gov NCT06270082 · fetched Nov 12, 2026
- Oral AHR Antagonist in Combination With Nivolumab in Patients With PD-1 Resistant Metastatic or Recurrent Head and Neck CancerPHASE1 · WITHDRAWN · started Mar 1, 2023ClinicalTrials.gov NCT05472506 · fetched Nov 12, 2026
- Oral TEAD Inhibitor Targeting the Hippo Pathway in Subjects with Advanced Solid TumorsPHASE1 · TERMINATED · started Jan 7, 2022ClinicalTrials.gov NCT05228015 · fetched Nov 12, 2026
- A Phase 1a/1b FIH Study of PY159 and in Combination With Pembrolizumab in Subjects With Advanced Solid TumorsPHASE1 · TERMINATED · started Nov 10, 2020ClinicalTrials.gov NCT04682431 · fetched Nov 12, 2026
- A Study of PY314 in Subjects With Advanced Solid TumorsPHASE1 · TERMINATED · started Oct 29, 2020ClinicalTrials.gov NCT04691375 · fetched Nov 12, 2026
- A Phase 1a/b Study of IK-175 as a Single Agent and in Combination With Nivolumab in Patients With Locally Advanced or Metastatic Solid Tumors and Urothelial CarcinomaPHASE1 · COMPLETED · started Dec 18, 2019ClinicalTrials.gov NCT04200963 · fetched Nov 12, 2026